- Country: USA
- Summary: Notice of Intent to Sole Source for 10X Genomics, Inc. Reagents Department (CCMD)
- UST Ref No: 120767978
- Deadline: 21 Jun 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 25-007587
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Notice of Intent to Sole Source for 10X Genomics, Inc. Reagents Department (CCMD)
Product Service Code: 6550 NAICS Code: 325413 Place of Performance:Bethesda, MD 20892
POTS: 25-007587
Description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested.
The National Institutes of Health (NIH), Office of Purchasing and Contracts on behalf of the Critical Care Medicine Department (CCMD) intends to award a firm fixed price Purchase Order to 10X Genomics, Inc, located in Pleasanton, California 94588-3260 on a sole source basis to provide 10X Genomics reagents.
The Critical Care Medicine Department is currently working on a project investigating the impact of SARS-CoV-2 infection on human brain tissues and cerebral organoid tissues at the single-cell level. The study utilizes 10X Genomics Dual Index TS Set A 96 rxn Kits, GEM-X Flex Sample Preparation v2 Kits, GEM-X Flex Gene Expression Chip, 4 chips kits, and GEM-X Flex Gene Expression Human 4 samples. These proprietary kits contain specialized reagents designed for the isolation and amplification of uniquely barcoded ribonucleic acid (RNA). The 10X Genomics platform uses microfluidics to separate individual cells into an emulsion with single gel beads and labels the RNA from each cell with a unique barcode for partitioning into libraries for sequencing.
The Critical Care Medicine Department has independently modified and validated the recommended protocols provided by 10X Genomics to be compliant with “Biosafety Level 3” (BSL-3 requirements). There are no substitutions of equipment or reagents for this study and used under the existing protocols. Any change of equipment or reagents would cause a stoppage of work, and the substitutions would have to undergo a re-validation process that could take up to one year or more. This ultimately would negatively impact patient care by causing a delay and ... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINNotice of Intent to Sole Source for 10X Genomics, Inc. Reagents Department (CCMD) - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Notice of Intent to Sole Source for 10X Genomics, Inc. Reagents Department (CCMD). This tender is published on USARFP under UST Ref No: 120767978 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-06-21.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
